Crossmark

Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncology

Crossref DOI link: https://doi.org/10.1007/s10147-019-01610-y

Published Online: 2020-01-24

Published Print: 2020-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Naito, Yoichi https://orcid.org/0000-0002-8490-9064
Mishima, Saori

Akagi, Kiwamu

Igarashi, Ataru

Ikeda, Masafumi

Okano, Susumu

Kato, Shunsuke

Takano, Tadao

Tsuchihara, Katsuya

Terashima, Keita

Nishihara, Hiroshi

Nishiyama, Hiroyki

Hiyama, Eiso

Hirasawa, Akira

Hosoi, Hajime

Maeda, Osamu

Yatabe, Yasushi

Okamoto, Wataru

Ono, Shigeru

Kajiyama, Hiroaki

Nagashima, Fumio

Hatanaka, Yutaka

Miyachi, Mitsuru

Kodera, Yasuhiro

Yoshino, Takayuki

Taniguchi, Hiroya
Funding

Funding for this research was provided by:

Japanese Society of Medical Oncology (N/A)

Japan Society of Clinical Oncology (N/A)

Ministry of Health, Labour and Welfare (H29 -measures against cancers- public-013)
License Information

Text and Data Mining valid from 2020-01-24

Version of Record valid from 2020-01-24
More Information

Article History

Received: 13 December 2019

Accepted: 20 December 2019

First Online: 24 January 2020

Compliance with ethical standards

:

: All committee members and peer review members were nominated by each Society, and the conflict of interest (COI) control is conducted by each Society’s regulation.

Document is current

Any future updates will be listed below